Time, technology and equipment constraints force many of us miss such great opportunities in knowledge and experience immediately. Sometimes, we partly succeed in catching up much later. Dr. McMillan, you have had extensive amount of discussions with Dr. Shankara Chetty in these two plus years. They are clinical gold mines. They need to be treasured for posterity. Please consider compiling them all into a printed book sometime. For many of us, used to book reading, it will be a boon. On a general note, anti histamines will have to be main line treatment, along with other organ/symptom specific medications. Slowly, but surely they will flush out the residual viral load completely. Their chemistry provides this capability. This could be true for vaccine induced organ issues also. Is there someway of studying the interaction between anti histamines and spike segments generated by m-RNA vaccines, even grossly at the Petri dish level first ?
Good on Dr Shankara Chetty for seeing his patients in person. I’ve lost much respect for the medical community in Canada for closing their doors in the time of most need by their patients. It doesn’t take a genius to figure out that lungs cannot be examined in a telephone call not to mention specific or generalised body pain. It was the worse care protocol to ever be in place.
Would like to add some more thoughts. The medical administrations may not agree immediately, but it is now necessary to name only infection induced symptoms (in unvaccinated ) differently from those experienced by the vaccinated (with or without infection). Inspite of the fact, they may look similar, even share most biology. The first one can be long covid, while the second one, more prominent one in populations, should be termed differently. On clinical side, both should be regarded as residual allergy as well, dormant mostly, but opening out sometimes ( what are the triggers ?). As allergy, anti histamines will have a major place in treatments. Many have experienced positive outcomes on such treatment. But a few may not respond well. Also, which anti histamines work well in a given situation, on a given patient ? Many questions remain to be unravelled, including the criterion for selection of a particular molecule ? For example, if we look at them as CADs at biological work, pKa is an important parameter. This is a field for some pathbreaking clinical research, that can serve humanity eternally.
Will there be another opportunity to watch this?
Unfortunately I am due to have a baby on 18th May so don’t want to book on and take a space in case I cannot attend ☹️
Time, technology and equipment constraints force many of us miss such great opportunities in knowledge and experience immediately. Sometimes, we partly succeed in catching up much later. Dr. McMillan, you have had extensive amount of discussions with Dr. Shankara Chetty in these two plus years. They are clinical gold mines. They need to be treasured for posterity. Please consider compiling them all into a printed book sometime. For many of us, used to book reading, it will be a boon. On a general note, anti histamines will have to be main line treatment, along with other organ/symptom specific medications. Slowly, but surely they will flush out the residual viral load completely. Their chemistry provides this capability. This could be true for vaccine induced organ issues also. Is there someway of studying the interaction between anti histamines and spike segments generated by m-RNA vaccines, even grossly at the Petri dish level first ?
Good on Dr Shankara Chetty for seeing his patients in person. I’ve lost much respect for the medical community in Canada for closing their doors in the time of most need by their patients. It doesn’t take a genius to figure out that lungs cannot be examined in a telephone call not to mention specific or generalised body pain. It was the worse care protocol to ever be in place.
Would like to add some more thoughts. The medical administrations may not agree immediately, but it is now necessary to name only infection induced symptoms (in unvaccinated ) differently from those experienced by the vaccinated (with or without infection). Inspite of the fact, they may look similar, even share most biology. The first one can be long covid, while the second one, more prominent one in populations, should be termed differently. On clinical side, both should be regarded as residual allergy as well, dormant mostly, but opening out sometimes ( what are the triggers ?). As allergy, anti histamines will have a major place in treatments. Many have experienced positive outcomes on such treatment. But a few may not respond well. Also, which anti histamines work well in a given situation, on a given patient ? Many questions remain to be unravelled, including the criterion for selection of a particular molecule ? For example, if we look at them as CADs at biological work, pKa is an important parameter. This is a field for some pathbreaking clinical research, that can serve humanity eternally.